Skip to main content
. 2004 Mar 18;141(6):881–903. doi: 10.1038/sj.bjp.0705698

Table 2.

Reported effects of three classes of PLA2 inhibitor against EDHF-type relaxations

PLA2 isoform cPLA2 iPLA2 sPLA2 Inhibits EDHF/species and artery type Reference
ONO-RS-082 +   + +Rabbit mesenteric Hutcheson et al. (1999)
        +Rat coronary Fulton et al. (1996)
        −Rat mesenteric Tanaka et al. (1999)
AACOCF3 ++ +   +Rabbit mesenteric Hutcheson et al. (1999); Hutcheson & Griffith (2000)
        +Rat coronary, mesenteric, cerebral Fulton et al. (1996); Adeagbo & Henzel (1998); You et al. (2002)
        −Guinea-pig coronary, carotid −bovine coronary Yamanaka et al. (1998); Quignard et al. (2002); Drummond et al. (2000)
PACOCF3 + ++ + +Rat cerebral You et al. (2002)
OOPC     + +Human subcutaneous Coats et al. (2001)
        +Rat coronary, mesenteric Fulton et al. (1996); Adeagbo & Henzel (1998)
HELSS   +   −Rabbit mesenteric Hutcheson et al. (1999)
        −Rat mesenteric, cerebral Adeagbo & Henzel (1998); You et al. (2002)

+/− signs reflect the ability of each compound to inhibit different PLA2 isoenzymes and relaxation. cPLA2, cytosolic Ca2+-dependent phospholipase A2; iPLA2, cytosolic Ca2+-independent phospholipase A2; sPLA2, secretory phospholipase A2. ONO-RS-082, 2-(p-amylcinnamoyl) amino-4-chlorobenzoic acid; AACOCF3, arachidonyl trifluoromethyl ketone; PACOCF3, palmitoyl trifluoromethyl ketone; OOPC, oleyloxyethyl phosphorylcholine; HELSS, haloenol lactone suicide substrate.